Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is part of a merged entity structure, inheriting emissions data from its parent company, Alcon Inc., at a cascade level of 2. However, no specific emissions figures or reduction targets have been disclosed.

Aerie Pharmaceuticals has not publicly committed to any specific climate initiatives or reduction targets, as indicated by the absence of documented reduction initiatives or Science-Based Targets Initiative (SBTi) commitments. The lack of emissions data and climate pledges suggests that Aerie Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy.

As the pharmaceutical industry increasingly focuses on sustainability, Aerie Pharmaceuticals may benefit from aligning its practices with industry standards and setting measurable targets to reduce its carbon footprint in the future.